# Safety Study of Gene-modified Autologous Fibroblasts in Recessive Dystrophic Epidermolysis Bullosa

> **NCT02493816** · PHASE1 · COMPLETED · sponsor: **King's College London** · enrollment: 5 (actual)

## Conditions studied

- Recessive Dystrophic Epidermolysis Bullosa

## Interventions

- **DRUG:** Gene-modified autologous fibroblasts

## Key facts

- **NCT ID:** NCT02493816
- **Lead sponsor:** King's College London
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2018-03
- **Final completion:** 2018-03
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2019-09-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02493816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02493816, "Safety Study of Gene-modified Autologous Fibroblasts in Recessive Dystrophic Epidermolysis Bullosa". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02493816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*